Axiisium · Products
Two products, one engine
The same fusion engine, packaged for two buyers and held to two different standards of reliability. One is reliable by architecture. One is reliable by accountability.
For pharma
Axiisium Enrich
Rank which trial candidates to sequence first for a molecular profile, so a sponsor fills an NPM1-defined cohort with fewer assays and a signed record of every selection.
In
Morphology, flow, and clinical data already collected on candidates.
Out
A calibrated, ranked sequence-first list with a signed selection record per patient.
Why it is safe
It ranks, it never decides. Sequencing always confirms enrollment, so the output cannot fail in a way that reaches a patient.
Reliable by architecture: a tunable recall floor bounds what it can miss, and confirmatory sequencing sits upstream of every decision. No diagnosis, no replacement for sequencing.
For the clinic
Axiisium Decide
A single signed assessment that evolves from day zero to final molecular: a provisional read while sequencing runs, an ELN-2022 risk class once genetics land, and a therapy-eligibility map, every claim tied to the signal that triggered it.
Day zero
Automated differential, blast percentage, NPM1 and core-binding-factor flags while molecular pends.
When genetics land
ELN-2022 risk class with measurable residual disease as a co-input and a confidence band.
Therapy map
On-label vs investigational flags, each bound to its triggering signal. FLT3 and the hard calls are deferred to molecular and the clinician.
Signed decision record
Powered by Project AIR
recordsigned capsule
modelaxiisium-fusion
inputsblake3:9f3a…c1d7
decided-bynamed clinician
signaturevalid
anchoredpublic log
✓ Tamper-evident, attributable, independently verifiable.
Reliable by accountability: every output shows its evidence and confidence, defers what it cannot prove, and never diagnoses autonomously. A hematopathologist retains the read.
Run AML trials, or treat AML patients?
Enrich is ready for pharma design partners now. Decide is in active development with clinical partners. If either is your world, we want to build it with you.